- About Bayer
- Contact Us
- HCP Login
- About Bayer
- Contact Us
- HCP Login
Bayer commits to the fight against Malaria in Southern Africa
- Johannesburg, April 24, 2017 – Bayer has committed to the fight against Malaria in Southern Africa as it announced the establishment of a partnership with Goodbye Malaria.
The partnership will see Bayer supporting Goodbye Malaria. in Ending Malaria for Good, specifically in the Southern African countries of Mozambique and Swaziland.
According to figures published in the 2016 WHO malaria report, malaria cases have fallen by 21 percent between 2010 and 2015 with malaria death rates decreasing by 29 percent over the same period, providing the impetus for more action to accelerate malaria elimination. In the last 15 years alone, vector-control has been responsible for preventing almost 80 percent of the total cases averted in Africa making vector-control key to reaching the goals of malaria elimination. However, despite the success in recent years, it has widely been recognised that the magnitude and global reach of the disease requiresthe ongoing engagement of all major stakeholders to work together to provide expertise, investment and innovation. “Bayer’s partnership with Goodbye Malaria is key to strengthening our respective commitment to expanding access to WHO-recommended vector control tools and to preventing people from contracting the disease,” explained Jose De Sousa, Country Group Head for Sub-Saharan Africa at Environmental Science, a Business Unit of the Crop Science Division at Bayer.
An initiative created and managed by African entrepreneurs, Goodbye Malaria has been raising funds for the past 4 years to deploy vector-control interventions, specifically indoor residual spraying (IRS), for preventing malaria cases in Mozambique, South Africa and Swaziland and works closely with the National Malaria Control Programmes in those countries to ensure optimum impact. Goodbye Malaria is also playing a major role in educating people that malaria elimination is possible, recruiting many of them to to join in the fight against malaria.
“We are excited to collaborate with Bayer to expand our malaria control programmes as we share the common belief that malaria elimination is possible thanks to vector-control solutions,” said Sherwin Charles, Goodbye Malaria’s co-founder. “In gathering local as well as international, public and private partners around this common objective we expect to accelerate its fulfilment and End Malaria for Good”.
Goodbye Malaria’s philosophy and engagement resonates with Bayer’s commitment to malaria elimination and its mission of Science For A Better Life. Bayer has been involved in the development and supply of effective vector control solutions for over 60 years, which includes core interventions such as indoor residual spraying (IRS) and long-lasting insecticide nets used in the fight against malaria.
“We are pleased to partner with Goodbye Malaria to jointly eliminate malaria in Mozambique and Swaziland by the year 2030,” said De Sousa. “The partnership established by Goodbye Malaria, which involves an international donor, government and the private sector, is the first of its kind and we are proud to be part of it. Through our vector-control solutions, together with the organisation we will contribute to protecting lives, to improve quality of life and to help maintain the social and economic development of thesecommunities”.
In line with the WHO call for harnessing innovation, Bayer continues to invest in the development of new vector-control solutions, specifically targeting the challenge of insecticide resistance. The most recent development, Fludora™ Fusion, is the first two-way combination product for IRS, which will also introduce a new mode of action. Submitted to the WHO Pesticides Evaluation Scheme (WHOPES) in October 2015, Bayer expects to have it available for use late in 2018.
“The management of insecticide resistance in malaria vectors relies largely on the implementation of IRS. Therefore, our partnership with Goodbye Malaria is particularly important. As Bayer continues to develop new tools to support the goal of ‘Ending Malaria for Good’, we can gain crucial insights from implementation challenges associated with IRS through this alliance,” adds Justin McBeath, Market Segment Manager Malaria Vector Control at Bayer.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Head of Communications, Southern Africa
Tel: +27 11 9215000/+27 82 8732423
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.